# Colistin and Rifampicin for MDR-Acinetobacter

> **NCT01577862** · PHASE3 · COMPLETED · sponsor: **University of Campania Luigi Vanvitelli** · enrollment: 210 (actual)

## Conditions studied

- Infection Due to Resistant Bacteria
- Pneumonia, Ventilator-Associated
- Hospital Acquired Pneumonia
- Infection of Bloodstream
- Infectious Disease of Abdomen

## Interventions

- **DRUG:** Colistin
- **DRUG:** Rifampicin

## Key facts

- **NCT ID:** NCT01577862
- **Lead sponsor:** University of Campania Luigi Vanvitelli
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2011-08
- **Final completion:** 2011-10
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2012-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01577862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01577862, "Colistin and Rifampicin for MDR-Acinetobacter". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01577862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*